Related Experiment Video
Updated: Aug 26, 2025

03:23
Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
Published on: May 10, 2024
881
Pediatric Eosinophilic Esophagitis: Searching for Serologic Markers
Simon Rabinowitz1, Liwei Yu2, Emily Hahm2
1Children's Hospital at Downstate, Division of Pediatric Gastroenterology, Downstate Health Sciences University, Brooklyn, NY, USA Simon.Rabinowitz@Downstate.edu.
Annals of Clinical and Laboratory Science
|October 5, 2022
Summary
This study found no reliable blood markers for diagnosing or monitoring eosinophilic esophagitis (EoE). Luminex assays did not identify any specific analytes associated with EoE in pediatric patients, highlighting the need for further research into diagnostic tools.
Area of Science:
- Immunology
- Gastroenterology
- Allergy
Background:
- Eosinophilic esophagitis (EoE) is a Th2-mediated allergic inflammatory disease of the esophagus.
- Current diagnosis relies on clinical symptoms and endoscopic biopsies showing esophageal eosinophilia.
- A reliable serologic marker for EoE diagnosis and monitoring is currently lacking.
Purpose of the Study:
- To identify a reliable serologic marker for eosinophilic esophagitis (EoE).
- To utilize custom-designed Luminex multiplex bead assays for screening potential biomarkers.
Main Methods:
- Luminex assays were used to measure serum levels of 11 analytes (including cytokines and immunoglobulins) in pediatric patients.
- The study cohort included patients with active EoE (n=30), EoE in remission (n=13), and healthy controls (n=34).
Main Results:
- No significant elevation or depression of the 11 tested analytes was observed in active EoE patients compared to other groups.
- None of the analytes correlated with peak esophageal eosinophil counts, endoscopic severity (EREFS), or esophageal thickness.
Conclusions:
- This study, the largest prospective survey of its kind, did not identify any reliable serologic markers for diagnosing or monitoring EoE.
- Luminex technology offers a rapid and cost-effective platform for screening multiple serum proteins in disease states.

